Empresa Capstone Therapeutics Corp Other OTC
Acciones
US14068E1091
Biotecnología e investigación médica
Resumen de negocios
Ventas por actividad
USD en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
Novel Peptides and Other Molecules
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84 % |
Ventas por región
USD en millones | 2021 | Peso | 2022 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 67 | 100,0 % | 62 | 100,0 % | -7,84 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Michael Toporek
CEO | Chief Executive Officer | 59 | 14/07/17 |
Edward Schultz
DFI | Director of Finance/CFO | - | - |
Matthew Lipman
BRD | Director/Board Member | 45 | 14/07/17 |
Jock Holliman
BRD | Director/Board Member | 70 | 01/09/87 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Jock Holliman
BRD | Director/Board Member | 70 | 01/09/87 |
Michael Toporek
CEO | Chief Executive Officer | 59 | 14/07/17 |
Matthew Lipman
BRD | Director/Board Member | 45 | 14/07/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 157 610 | 157 610 ( 100,00 %) | 0 | 100,00 % |
Información de la empresa
Capstone Therapeutics Corp.
1275 West Washington Street Suite 104
85281, Tempe
+602-286-5520
http://www.capstonethx.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+29,03 % | 49,18 mil M | |
-0,10 % | 42,11 mil M | |
+43,45 % | 40,37 mil M | |
-5,26 % | 28,85 mil M | |
+11,48 % | 26,09 mil M | |
-22,74 % | 18,71 mil M | |
+9,06 % | 13,26 mil M | |
+30,01 % | 12,32 mil M | |
-1,51 % | 11,99 mil M |